Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11572211 | 0.98 | NOD1 (0.49) | NOD1CA2SLC6A5HDAC2MME | |
| SCHEMBL1298940 | 0.95 | NOD1 (0.53) | NOD1CA2SLC6A5FOLH1SLC1A2 | |
| SCHEMBL5533319 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5535811 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5535474 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5529710 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5535452 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5535718 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5533485 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 | |
| SCHEMBL5530124 | 0.93 | NOD1 (0.55) | NOD1SLC6A5FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58010555-A | — | — | None | — | — | JP | disclosed |
| JP-58010556-A | — | — | None | — | — | JP | disclosed |
| JP-58004758-A | — | — | None | — | — | JP | disclosed |
| JP-54076532-A | — | — | None | — | — | JP | disclosed |
| JP-60058956-A | — | — | None | — | — | JP | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20220111003-A1 | NEUROPROTECTIVE PEPTIDES | ARGENICA THERAPEUTICS PTY LTD (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3976061-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | The University of Chicago (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-109481732-B | 3D cell printing material based on PEG chitosan-gelatin system and application thereof | 中国科学院理化技术研究所 | 2021-07-27 | — | — | CN | disclosed |
| WO-1995024424-A1 | CYCLIC PEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0435235-B1 | Isoquinoline derivatives and salts thereof as protease inhibitors. | SNOW BRAND MILK PRODUCTS CO LTD (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5116985-A | Protease Inhibitors, Antitrypsin Agents | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0435235-A1 | Isoquinoline derivatives and salts thereof as protease inhibitors. | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1991-07-03 | — | — | EP | disclosed |
| JP-S6058956-A | PRODUCTION OF P-ETHOXYCARBONYLPHENYL GUANIDINOCAPROATE ESTER | TEIKOKU CHEM IND CORP LTD | 1985-04-05 | — | — | JP | disclosed |
| JP-S5810555-A | PREPARATION OF GUANIDINOCAPROIC ACID P-ETHOXYCARBONYLPHENYL | TEIKOKU CHEM IND CORP LTD | 1983-01-21 | — | — | JP | disclosed |
| JP-S5810556-A | PREPARATION OF GUANIDINOCAPROIC ACID P-ETHOXYCARBONYLPHENYL ESTER | TEIKOKU CHEM IND CORP LTD | 1983-01-21 | — | — | JP | disclosed |
| JP-S584758-A | PREPARATION OF GUANIDINOCAPROIC ACID PHENYL ESTER | TEIKOKU CHEM IND CORP LTD | 1983-01-11 | — | — | JP | disclosed |
| US-4182897-A | ENZYME INHIBITORS FOR PROTEOLYTIC ENZYMES | TORII & CO., LTD. (JP) | 1980-01-08 | — | — | US | disclosed |
| JP-S5476532-A | PREPARATION OF GUANIDINO-FATTY ACID DERIVATIVE | ONO PHARMACEUT CO LTD | 1979-06-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220111003-A1 | NEUROPROTECTIVE PEPTIDES | ARGLU1, BDNF, IAPP | NOD1 4205/4885CA2 2795/4885SLC6A5 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.